Positioned for sustained growth and increasing value

1. Profitable commercial-stage company with two marketed anti-infective products
2. Strong financial position with sustainable cash flows supporting continued growth
3. Leading strategic position in an area of high unmet medical need, addressing rising challenges in treating severe bacterial and fungal infections
4. Current Phase 3 pipeline assets alone create opportunity to double 2025 in-market sales
5. Proven, capital‑efficient and asset-light business model leveraging strong global partnerships

Updated August 18, 2026
 

Download

Archive

Archive

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here.  Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management.  Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

In July 2020, Basilea issued CHF 97.085 million aggregate principal amount of convertible senior unsecured bonds (the “2027 Bonds”, ISIN: CH0554992062; SSN: 55'499'206). The 2027 Bonds bear interest at a fixed rate of 3.25% per year and mature on July 28, 2027, unless earlier redeemed or converted. As of July 24, 2026, following the repurchase of a portion of the bonds, CHF 71.020 million remain outstanding. For further information on the convertible bonds, please refer to the current financial report.

At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics form the basis of our ESG strategy. They are key for the setting of goals and are at the core of our ESG-related reporting. In 2024, we further developed our ESG strategy by defining KPIs for the individual focus topics. In 2025, a first sustainability report was developed in accordance with the GRI Standards and published as part of the full-year report 2025.

ESG report 2025
Key elements of Basilea's ESG strategy - update 2024
Key elements of Basilea's ESG strategy - initial release 2023

Articles of Association

Articles of Association (April 2026
Statuten (April 2026)
 

Archive

Code of Conduct

Code of Conduct
Verhaltenskodex

Organisational Regulation

Organisational Regulation
 

Archive

Leadership

Boards of directors
Management committee
Extended management committee

Significant shareholders

SIX Website

News subscription form
Investor Relations contact
Follow us on LinkedIn